In the wake of multiple clinical setbacks, including two late-stage failures for its lead asset ganaxolone, Marinus Pharmaceuticals has initiated another round of layoffs while it explores strategic alternatives. Following a 20% workforce reduction earlier this year and a subsequent round of job cuts last month, this time the company is trimming approximately 45% of staff to further preserve cash.
https://firstwordpharma.com/story/5912314